J1850 – Injection, kanamycin sulfate, up to 75 mg
HCPCS Level II code · J codes: Drugs Administered Other Than Oral Method
HCPCS codeJ1850
- Long description
- Injection, kanamycin sulfate, up to 75 mg
- Short description
- Kanamycin sulfate 75 mg inj
- Pricing indicator
51Drugs- Medicare coverage
DSpecial coverage instructions apply- BETOS category
O1EOther drugs- Added
- January 1, 1982
- Last change
- April 1, 2024 – No change
- Termination date
- March 31, 2024
Frequently asked questions
What is HCPCS code J1850?
J1850 is a HCPCS Level II code for injection, kanamycin sulfate, up to 75 mg. It was discontinued on March 31, 2024.
Does Medicare cover J1850?
The HCPCS file lists coverage code D: Special coverage instructions apply. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby J codes
- J1826 – Injection, interferon beta-1a, 30 mcg
- J1830 – Injection, interferon beta-1b, 0.25 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
- J1833 – Injection, isavuconazonium, 1 mg
- J1834 – Injection, isoniazid, 1 mg
- J1835 – Injection, itraconazole, 50 mg
- J1836 – Injection, metronidazole, 10 mg
- J1837 – Injection, posaconazole, 1 mg
- J1840 – Injection, kanamycin sulfate, up to 500 mg
- J1885 – Injection, ketorolac tromethamine, per 15 mg
- J1890 – Injection, cephalothin sodium, up to 1 gram
- J1920 – Injection, labetalol hydrochloride, 5 mg
- J1921 – Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg
- J1930 – Injection, lanreotide, 1 mg
- J1931 – Injection, laronidase, 0.1 mg
- J1932 – Injection, lanreotide, (cipla), 1 mg
- J1938 – Injection, furosemide, 1 mg
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.